PHC Corporation and NovaScan, Inc. Join Forces to Investigate New Technology to Detect Non-Melanoma Skin Cancer!

PHC Corporation and NovaScan, Inc. are excited to announce a collaboration to explore the potential of MarginScanTM, an investigational “ex vivo” medical device that could help physicians detect non-melanoma skin cancers (NMSC). With the support of PHC President Nobuaki Nakamura and NovaScan CEO Craig Davis, this ambitious project seeks to revolutionize the way NMSC is detected and treated.

PHC Group*1, a global healthcare leader, is proud to present its subsidiary PHC – a company dedicated to developing, manufacturing, selling, and servicing solutions in the domains of diabetes management, healthcare solutions, and diagnostics & life sciences for over 30 years.

To further provide effective medical treatment, PHC’s In Vitro Diagnostics Division has recently collaborated with NovaScan – a U.S. company specializing in clinical-stage diagnostics and tissue detection in the oncology field.

With its proprietary technology for detecting cancer tissue in real-time, NovaScan is now expanding its business to commercialize its point-of-care platform to medical institutions around the world.

The American Academy of Dermatology estimates that one in five Americans will develop skin cancer in their lifetime, and the vast majority of these will be NMSC. To help reduce patient morbidity and improve outcomes, PHC and NovaScan are collaborating to explore the feasibility of a device, MarginScanTM, which has the potential to enable comprehensive real-time margin detection for NMSC.

This device could support Mohs surgery procedures, the only modality for skin cancer treatment that involves comprehensive intraoperative margin assessment. The collaboration will integrate PHC’s manufacturing excellence with NovaScan’s advanced technology to detect carcinoma tissue, and they will explore other potential strategic collaborations to provide new value to patients and healthcare providers in the oncology field.

Hiroyuki Tokunaga, Member of the Board of PHC and Director of its In Vitro Diagnostics Division, is thrilled to be collaborating with NovaScan to provide revolutionary solutions in the pathology diagnostics field.

With PHC’s expertise in highly reliable medical device development and NovaScan’s cutting-edge technology, together they will be pushing the boundaries of healthcare and providing high value-added solutions. PHC is dedicated to speeding up the development of point-of-care technology to make testing more convenient and contribute to their mission of improving the quality of healthcare worldwide.

Craig Davis, CEO of NovaScan, is thrilled to announce a collaboration with PHC Group, a world-renowned provider of oncology diagnostics solutions and medical devices. Thanks to their revolutionary platform technology, MarginScanTM, cancer can be detected in vivo and ex vivo in real time without expensive capital equipment or lengthy clinician learning curves. With PHC Group’s assistance, MarginScanTM has the potential to become a standard of care procedure for the most common cancers on the planet.

About PHC Corporation

PHC Corporation, a subsidiary of PHC Group, has been dedicated to improving the health and wellbeing of society since 1969. We offer an extensive range of medical solutions, including medical devices, research and medical support equipment, and diabetes management, healthcare and diagnostics & life sciences solutions in over 125 countries worldwide.

Our mission is to provide healthcare solutions that have a positive impact on people’s lives and make a real difference in the world. With our innovative solutions, we strive to be a leader in the global healthcare industry.

About NovaScan, Inc.

NovaScan is a venture-backed, clinical stage oncology company revolutionizing the way cancer is detected and stratified. With its low cost, point of care platform, NovaScan is able to provide real time cancer detection and stratification for lung, breast, skin, and GI cancers. NovaScan is leading the way in providing fast, accurate, and cost-effective cancer diagnostics.

Leave a Comment